JP2022554284A5 - - Google Patents
Info
- Publication number
- JP2022554284A5 JP2022554284A5 JP2022525329A JP2022525329A JP2022554284A5 JP 2022554284 A5 JP2022554284 A5 JP 2022554284A5 JP 2022525329 A JP2022525329 A JP 2022525329A JP 2022525329 A JP2022525329 A JP 2022525329A JP 2022554284 A5 JP2022554284 A5 JP 2022554284A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- genetically modified
- target
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928524P | 2019-10-31 | 2019-10-31 | |
| US62/928,524 | 2019-10-31 | ||
| PCT/US2020/058565 WO2021087466A1 (en) | 2019-10-31 | 2020-11-02 | Generation of cd38 knock-out primary and expanded human nk cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022554284A JP2022554284A (ja) | 2022-12-28 |
| JP2022554284A5 true JP2022554284A5 (cg-RX-API-DMAC7.html) | 2024-03-14 |
Family
ID=75715400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525329A Pending JP2022554284A (ja) | 2019-10-31 | 2020-11-02 | Ｃｄ３８ノックアウト初代および増殖ヒトｎｋ細胞の生成 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220401482A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4051297A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022554284A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220093337A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114867485A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020375053A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022008215A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156509A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292584A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005051A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021087466A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| MX2023014356A (es) * | 2021-06-02 | 2024-02-15 | Metagenomi Inc | Sistemas crispr de clase ii, tipo v. |
| KR20240051112A (ko) | 2021-07-01 | 2024-04-19 | 인답타 세라뷰틱스 인코포레이티드 | 조작된 자연 살해(nk) 세포 및 관련 방법 |
| WO2023081200A2 (en) * | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
| JP2025001053A (ja) * | 2021-11-05 | 2025-01-08 | 学校法人東海大学 | 劇症型ｎｋ白血病に対する治療標的の同定 |
| KR20250029015A (ko) | 2022-03-07 | 2025-03-04 | 사노피-아벤티스 유.에스. 엘엘씨 | 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도 |
| CN114921416B (zh) * | 2022-05-12 | 2023-05-23 | 广东普罗凯融生物医药科技有限公司 | 一种nk细胞及其制备方法 |
| US20250375524A1 (en) | 2022-06-30 | 2025-12-11 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| WO2024124242A2 (en) * | 2022-12-09 | 2024-06-13 | Research Institute At Nationwide Children's Hospital | Combination cd38ko/car ki nk cell immunotherapy for dual targeting with cd38 monoclonal antibodies |
| US20260207666A1 (en) * | 2022-12-09 | 2026-07-23 | Research Institute At Nationwide Children's Hospital | Cd38 as integration site for enhanced function of gene-modified immune cells |
| EP4651880A1 (en) * | 2023-01-17 | 2025-11-26 | Research Institute at Nationwide Children's Hospital | Methods of targeting glycogen synthase kinase 3 beta in nk cells |
| CN116679065B (zh) * | 2023-07-31 | 2023-11-14 | 北京大学人民医院 | 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品 |
| WO2025213127A1 (en) | 2024-04-05 | 2025-10-09 | Indapta Therapeutics, Inc. | Treatment of autoimmune diseases or conditions with natural killer cells |
| WO2025245399A1 (en) | 2024-05-23 | 2025-11-27 | Indapta Therapeutics, Inc. | Method of treating cancer with natural killer cells |
| WO2026050706A1 (en) * | 2024-08-30 | 2026-03-05 | Aventis Inc. | Nk cells having reduced cd38 expression and method for producing |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US128A (en) | 1837-02-16 | Holdback for sleds | ||
| FR1601438A (cg-RX-API-DMAC7.html) | 1968-10-17 | 1970-08-24 | ||
| US10117899B2 (en) * | 2013-10-17 | 2018-11-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| EP3154581B1 (en) * | 2014-06-16 | 2019-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells |
| US10738278B2 (en) * | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| JP6754361B2 (ja) * | 2014-12-16 | 2020-09-09 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 若年型バッテン病のための遺伝子療法 |
| JP7033453B2 (ja) * | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法 |
| MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| JP7653759B2 (ja) * | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| AU2017248259A1 (en) * | 2016-04-07 | 2018-10-25 | Bluebird Bio, Inc. | Chimeric antigen receptor T cell compositions |
| EP3581190B1 (en) * | 2016-12-09 | 2021-03-10 | ONK Therapeutics Limited | Engineered natural killer cells and uses thereof |
| BR112020011017A2 (pt) * | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
| AU2019271366B2 (en) * | 2018-05-16 | 2026-02-26 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins |
-
2020
- 2020-11-02 CN CN202080090071.9A patent/CN114867485A/zh active Pending
- 2020-11-02 EP EP20882013.4A patent/EP4051297A4/en active Pending
- 2020-11-02 WO PCT/US2020/058565 patent/WO2021087466A1/en not_active Ceased
- 2020-11-02 US US17/773,755 patent/US20220401482A1/en not_active Abandoned
- 2020-11-02 KR KR1020227018144A patent/KR20220093337A/ko not_active Ceased
- 2020-11-02 MX MX2022005051A patent/MX2022005051A/es unknown
- 2020-11-02 IL IL292584A patent/IL292584A/en unknown
- 2020-11-02 AU AU2020375053A patent/AU2020375053A1/en active Pending
- 2020-11-02 CA CA3156509A patent/CA3156509A1/en active Pending
- 2020-11-02 JP JP2022525329A patent/JP2022554284A/ja active Pending
- 2020-11-02 BR BR112022008215A patent/BR112022008215A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diorio et al. | Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks | |
| Golomb et al. | p53 and ribosome biogenesis stress: the essentials | |
| Van Vlierberghe et al. | The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia | |
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| Walecki et al. | Androgen receptor modulates Foxp3 expression in CD4+ CD25+ Foxp3+ regulatory T-cells | |
| Katsogiannou et al. | The hallmarks of castration-resistant prostate cancers | |
| Cycon et al. | Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B‐cell lymphoma | |
| CN114867485A (zh) | Cd38敲除的原代和扩增的人nk细胞的生成 | |
| US20220062394A1 (en) | Methods for identifying neoantigens | |
| Vago et al. | Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia | |
| Testa et al. | CAR-T cell therapy in B-cell acute lymphoblastic leukemia | |
| WO2021043804A1 (en) | Immunotherapy targeting tumor neoantigenic peptides | |
| Gallouet et al. | Macrophage production and activation are dependent on TRIM33 | |
| Groza et al. | Recent advancements in the study of breast cancer exosomes as mediators of intratumoral communication | |
| Sakemura et al. | Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies | |
| WO2019191501A1 (en) | Use of histone modifiers to reprogram effector t cells | |
| JP2024513514A5 (cg-RX-API-DMAC7.html) | ||
| Kishimoto et al. | Molecular pathogenesis of follicular lymphoma | |
| Petri et al. | Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities | |
| JP2021516666A5 (cg-RX-API-DMAC7.html) | ||
| Cheema et al. | Under the hood: evidence-based review of allogeneic chimeric antigen receptor T cells for hematologic malignancies | |
| Chang et al. | Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system | |
| Zak et al. | Positive and negative roles of myeloid cells in cancer immunotherapy | |
| Konrad et al. | Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes | |
| EP4048304A1 (en) | Immunotherapy targeting tumor neoantigenic peptides |